Trevi Therapeutics Inc - Asset Resilience Ratio
Trevi Therapeutics Inc (TRVI) has an Asset Resilience Ratio of 80.05% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Trevi Therapeutics Inc (TRVI) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Trevi Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Trevi Therapeutics Inc.
Liquid Assets Composition Over Time
This chart breaks down Trevi Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore TRVI long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $264.57 Million | 80.05% |
| Total Liquid Assets | $264.57 Million | 80.05% |
Asset Resilience Insights
- Very High Liquidity: Trevi Therapeutics Inc maintains exceptional liquid asset reserves at 80.05% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Trevi Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Trevi Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Trevi Therapeutics Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Trevi Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 87.54% | $169.35 Million | $193.44 Million | +21.25pp |
| 2024-12-31 | 66.30% | $73.53 Million | $110.90 Million | +9.73pp |
| 2023-12-31 | 56.57% | $50.57 Million | $89.40 Million | -31.16pp |
| 2022-12-31 | 87.73% | $107.92 Million | $123.02 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $38.48 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $20.49 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $22.23 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $8.41 Million | -- |
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction i… Read more